Loading
collectionsCollection
NICE technology appraisals
NICE technology appraisals say whether the NHS will pay, and why. They are the most transparent HTA record in the world.
Overview
NICE technology appraisals record England's cost-effectiveness decisions for cancer drugs, with committee papers and prices where disclosed, so they say whether the NHS will pay and why. Published continuously by the National Institute for Health and Care Excellence, the TA documents include the evidence review and often the only public sight of the confidential discounts being negotiated, which makes them the most transparent HTA record in the world. The documents are public. On OnCo the source is tagged source and data, and it is linked from the institution record National Institute for Health and Care Excellence and from the Global access and affordability roadmap.
Holds
England's cost-effectiveness decisions for cancer drugs, with committee papers and prices where disclosed.
Licence
Public
Maintainer
National Institute for Health and Care Excellence
Similar pages
- CollectionDimensions
Shares the tags source, data.
- CollectionEMA news and CHMP meeting highlights
Shares the tags source, data.
- CollectionSemantic Scholar
Shares the tags source, data.
- CollectionEvaluate Vantage
Shares the tags source, data.
- CollectionNICE cancer guidance and technology appraisals (UK)
Shares National Institute for Health and Care Excellence, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
- InstitutionNational Healthcare Security Administration
Shares National Institute for Health and Care Excellence, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
- InstitutionEuropean Medicines Agency
Shares National Institute for Health and Care Excellence, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.